Document is current
Any future updates will be listed below
-
Authors
Zhang, Xue
Nakajima, Kenichi https://orcid.org/0000-0001-7188-8746
Acampa, Wanda
Assante, Roberta
D’Antonio, Adriana
Okuda, Koichi
Yokoyama, Kunihiko
Kinuya, Seigo
-
Funding
Funding for this research was provided by:
JSPS Grants-in-Aid for Scientific Research (23K07203)
Kanazawa University
- License Information
-
More Information
Article History
Received: 9 January 2025
Accepted: 18 May 2025
First Online: 2 June 2025
Declarations
:
: K. Nakajima collaborates with Spectrum Dynamic Medical, Caesarea, Israel, and PDRadiopharma, Inc., Tokyo, Japan. K. Nakajima has a collaborative research agreement with PDRadiopharma (Tokyo, Japan), which markets 123I-MIBG in Japan. He belonged to a department endowed by PDRadiopharma, Nihon Medi-Physics (Tokyo, Japan), and Siemens Healthcare (Tokyo, Japan) by March, 2024.
: All methods were applied according to the ethical standards enshrined in the Declaration of Helsinki (2013 amendment) or comparable ethical standards. The Ethics Committee at Kanazawa University approved this retrospective study (Approval number: 3266/2019–244) and waived the need for patient consent to participate.
: Not applicable.
